Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Scherlinger

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|April 23, 2026
Reprogramming CAR T cells across genetic, epigenetic, metabolic and microenvironmental axes to improve efficacy and safety in cancer and autoimmune diseaseMarc Scherlinger
Joint Bone Spine|July 26, 2023
Platelets are a major player and represent a therapeutic opportunity in systemic lupus erythematosusMarie Robert, Marc Scherlinger
Annals of the Rheumatic Diseases|March 24, 2021
Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting'Marc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|March 15, 2018
Additional response to the correspondence: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and BennuciMarc Scherlinger, Thierry Schaeverbeke
The Lancet. Rheumatology|June 29, 2026
Low-dose and very low-dose glucocorticoids: which low is low risk?Marc Scherlinger, Laurent Chiche
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 31, 2024
CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?Jérôme Avouac, Marc Scherlinger,
Annals of the Rheumatic Diseases|January 6, 2019
'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?Marc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|January 28, 2018
Response to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and BenucciMarc Scherlinger, Thierry Schaeverbeke
Nature Immunology|November 23, 2021
Shortage of aspartate in mitochondria fuels arthritisMarc Scherlinger, George C Tsokos
Autoimmunity Reviews|June 12, 2021
Reactive oxygen species: The Yin and Yang in (auto-)immunityMarc Scherlinger, George C Tsokos
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|April 23, 2026
Reprogramming CAR T cells across genetic, epigenetic, metabolic and microenvironmental axes to improve efficacy and safety in cancer and autoimmune diseaseMarc Scherlinger
Joint Bone Spine|July 26, 2023
Platelets are a major player and represent a therapeutic opportunity in systemic lupus erythematosusMarie Robert, Marc Scherlinger
Annals of the Rheumatic Diseases|March 24, 2021
Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting'Marc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|March 15, 2018
Additional response to the correspondence: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and BennuciMarc Scherlinger, Thierry Schaeverbeke
The Lancet. Rheumatology|June 29, 2026
Low-dose and very low-dose glucocorticoids: which low is low risk?Marc Scherlinger, Laurent Chiche
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 31, 2024
CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?Jérôme Avouac, Marc Scherlinger,
Annals of the Rheumatic Diseases|January 6, 2019
'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?Marc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|January 28, 2018
Response to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and BenucciMarc Scherlinger, Thierry Schaeverbeke
Nature Immunology|November 23, 2021
Shortage of aspartate in mitochondria fuels arthritisMarc Scherlinger, George C Tsokos
Autoimmunity Reviews|June 12, 2021
Reactive oxygen species: The Yin and Yang in (auto-)immunityMarc Scherlinger, George C Tsokos
Pageof 8